Blood stream infections (BSI) or Sepsis is a life-threatening condition that affects more than 48 million people worldwide and contributes to approximately 11 million deaths per year. Current standard of care methods like blood culture can take days for results to be available. Sequencing to detect and identify a bloodstream pathogen is a manual process, with highly variable times to result. DNAe has developed a sample-to-result, NGS-based, BSI/AMR Test on our prototype LiDia-SEQ™ platform, that detects bacterial targets, with select antimicrobial resistance markers (AMR), and fungal targets directly from whole blood. The LiDia-SEQ™ platform consists of the system, test kits, and software.

Q: What are the latest updates on DNAe’s LiDia-SEQ™ platform, and the delivery of rapid, near-patient tests for bloodstream infection/antimicrobial resistance (BSI/AMR)?

A: We’re currently at a very exciting phase in the delivery of our LiDia-SEQ™ Next-Generation Sequencing (NGS)-based, sample-to-report diagnostic platform. What we’ve developed is the only device in the world that allows you to go straight from a tube sample of blood direct to sequencing and diagnosis – within the same day, in a single box solution, and with fully (automated) hands-free operation.

London, UK and Carlsbad, CA, USA – November 5th 2025: DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today announces that it will be presenting brand-new data on novel testing applications in oncology monitoring, bloodstream infection (BSI) detection and combatting antimicrobial resistance (AMR) at the Association for Molecular Pathology (AMP) Annual Meeting and Expo. AMP 2025 is being held at the Thomas M. Menino Convention & Exhibition Center in Boston, US from November 11th – 15th 2025.

Blood liquid biopsy contains circulating cell-free DNA (cfDNA), a portion of which may be shed from tumors. This circulating tumor-derived DNA (ctDNA) can be tested to identify cancerous mutations. DNAe is developing the first rapid, sample-to-result, NGS-based solution.

Sepsis is a significant life-threatening condition with 48.9 million cases per year leading to 11 million deaths worldwide1. Patient outcomes are directly related to the timely diagnosis and identification of the pathogen and administration of the appropriate antibiotic treatment.

DNAe, the next generation sequencing (NGS) company developing a novel diagnostics platform for use at the point-of-need, announces that it will be presenting new clinical data on testing applications in cancer monitoring, bloodstream infection (BSI) detection and combatting antimicrobial resistance (AMR).

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, provides a business update on its LiDia-SEQ™ technology platform, and operational activities as the Company accelerates preparation of its commercialization strategy and roadmap.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has expanded its Commercial team, appointing Supriya Mathur to the newly created role of Global Head of Communications.

DNAe co-founder Professor Christofer Toumazou has been officially announced as a laureate of the 2021 UNESCO-Equatorial Guinea International Prize for Research in the Life Sciences – the first UK winner.

Together with Imperial College London (‘Imperial’), DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support development of its next generation sequencing (NGS)-based diagnostic platform for use in cancer monitoring.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announces positive results from internal tests using its LiDia-SEQ™ sequencing technology to identify SARS-CoV-2. The SARS-CoV-2 coronavirus is the cause of the COVID-19 pandemic currently causing extensive mortality, morbidity and disruption globally.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announced that the US Food and Drug Administration (FDA) has granted it a “Breakthrough Device” designation for its pioneering platform and first assay.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today provides an update on its response to the COVID-19 pandemic and announces that internal testing is underway to evaluate use of the LiDia-SEQ™ sequencing technology for the current SARS-CoV-2 pandemic and to help in containing future outbreaks.

DNAe, the next generation sequencing (NGS) company developing novel diagnostics for use at the point-of-need, provides an update on its significant research and development (R&D) and operational achievements in 2019.